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A B s T r A C T
Background: Clinical practice guidelines are often 
evidence-based. However, it is inevitable that there are value 
judgements in the practical recommendations contained in 
the guidelines. in order to see if patients are ultimately being 
supplied with sufficient information to help them make 
treatment decision, we determined 1) which value judgements 
influence the process of developing guidelines for palliative 
chemotherapy, and 2) whether these value judgements were 
made explicit in the final guideline report.
Methods: We studied the development process of six dutch 
oncology guidelines in which palliative chemotherapy plays 
a substantial role. We observed the guideline development 
groups (GdGs), conducted semi-structured interviews 
with individual GdG members (including the chairs), and 
analysed the minutes of GdG meetings and subsequent 
versions of the guidelines. A value judgement was defined 
as a statement about the value of a patient outcome with 
regard to palliative chemotherapy.
results: We identified the following value judgements in the 
process of guideline development: 1) consensus on what should 
be considered as valuable minimum patient outcomes, 2) 
preference for tailored treatment in situations where there is no 
evidence of treatment effect, 3) preference for ‘doing something’ 
even when there is sufficient evidence of no effect, and 4) the 
patient outcome of ‘prolonging life’. These value judgements, 
however, were not reported in the final guideline. 
Conclusion: At least the last two value judgements mentioned 
are relevant for patients with incurable metastatic cancer 
in making decisions whether to undergo chemotherapy 
and what kind. Value judgements should be made explicit 
in guidelines, so that clinicians can transparently discuss 
treatment options with individual patients. 
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i N T r o d U C T i o N
Based on the best available research evidence, clinical 
practice guidelines aim to standardise and improve the 
quality of health care by rendering medical action more 
‘objective’.1,2 Clinicians use these guidelines in making 
decisions on the best treatment for their patients. In 
the Netherlands, guidelines are developed according to 
the principles of evidence-based medicine, often with 
methodological support from the Dutch Institute for 
Healthcare Improvement (CBO).3-5
A guideline development process includes the following 
steps: 1) formulation of clinical questions based on an 
analysis of the most relevant problems in practice, 2) 
systematic collection, critical appraisal and grading of 
evidence, and 3) translation of evidence into practical 
recommendations. This third step includes considering 
factors other than evidence, such as safety issues, patient 
perspective, organisational barriers and cost.6,7 
When formulating a recommendation, developers determine 
whether a certain treatment will be recommended as a 
standard of care. It is inevitable that value judgements are 
used in this process. For example, recommendations need 
value judgements about the value of life when health is 
impaired, the meaningfulness of aggressive treatment, 
and the acceptability of side effects and risks.8 Although 
the same body of evidence is used both nationally and 
internationally, these value judgements account for many 
variations between clinical practice guidelines.9,10
63
F e b r u a r y  2 0 0 9 ,  V o l .  6 7 ,  N o .  2
De Kort, et al. Value judgements remain implicit.
It is particularly important to take value judgements 
into consideration when developing guidelines for the 
treatment of metastatic cancer. Because no curative 
options are available, metastatic cancer patients are facing 
death. For these patients, guidelines may recommend 
offering chemotherapy as an option for prolonging life 
or reducing symptoms. Chemotherapy, however, can 
also cause serious side effects and may burden the 
patient with visits to the hospital. According to principles 
of shared decision-making, the patient and his or her 
physician need to weigh up the pros and cons of different 
treatment options, including the possibility of ‘watchful 
waiting’.11 One patient’s value judgements may differ 
from those of another patient, which may differ from 
those of a physician, which may in turn differ from those 
of another physician. Nowadays, physicians tend to be 
less paternalistic and to share decision-making with their 
patients. Therefore, both physicians and patients should be 
aware of the value judgements in these cancer guidelines 
in making decisions on treatment. 
It is unknown how value judgements are incorporated 
into guidelines for ‘optimal care’ for metastatic cancer 
patients. The purpose of our study was to answer the 
following questions: 1) Which value judgements were used 
in developing guidelines for palliative chemotherapy? and 
2) Have these value judgements been made explicit in the 
final guideline report? 
M E T H o d s
Between January 2005 and January 2008, we conducted 
a longitudinal observational study of the development 
process of six national oncology guidelines in the 
Netherlands. We selected cancer guidelines for areas in 
which palliative chemotherapy plays a substantial role: 
lung cancer, oesophageal cancer, breast cancer, prostate 
cancer, ‘cancer with pain,’ and colorectal cancer. 
data collection
Different methods were used to collect data: 1) observing 
guideline development group (GDG) meetings as an auditor;12 
2) in-depth, semi-structured interviews (of one hour in 
length) with the members of the GDGs;13 and 3) text analysis 
of meeting minutes, draft and final guideline documents. 
GDG meetings were observed at crucial stages in the 
guideline development process: at the start (scoping and 
defining clinical questions), halfway (formulation of 
recommendations), and the end (endorsement of the final 
guideline). In addition, meetings were observed when 
palliative chemotherapy was on the agenda. At the start 
of our study, one guideline (lung cancer) had already been 
completed and another guideline (oesophageal cancer) was 
nearly ready. For these guidelines we could not observe their 
GDG meetings (table 1). One guideline meeting concerned 
the update of a guideline (just one meeting). We observed 
three to five meetings for the other three guidelines. In 
total, 14 meetings were selected for observation. 
All chairs of the GDGs were asked for an interview. Key 
members of all GDGs were identified and asked for an 
interview, also if they were involved in metastatic cancer 
care. In total we selected 20 professionals (including 
chairs) from different disciplines, including medical 
oncologists, a palliative care physician, a radiotherapist, a 
urologist, methodologists and also a patient representative 
(see also table 1). Two professionals, one chair and one 
radiotherapist, declined due to time constraints. 
The results of text analysis were used as input for the GDG 
observations and interviews. If available, GDG observations 
were also used as input for interviews. Analysing the 
next versions of guideline documents allowed us to trace 
the changes that resulted from the GDG meetings we 
observed. 
Observations and interviews were recorded on tape and 
transcribed. The interviews included open questions 
related to the specific guideline documents and relevant 
events during observations (table 2). 
Table 1. Guidelines selected and data sources used
Guideline (time of start and time 
of publication of final report)
documents analysed Number of GdG observations Number of interviews 
Non-small cell lung cancer 
(2002 - Oct 2004)
Minutes, final guideline text None 3 (Jan 2005)
Oesophageal cancer
(2002 - Dec 2005)
Minutes, final guideline text None 5 (Jan - Mar 2005)
Breast cancer
(2002, revision 2004, update 
2006)
Minutes, final guideline text 1 update (Mar 2006) 4 (Jan - Feb 2005)
Prostate cancer
(Jan 2003 - Jul 2007)
Minutes, drafts and final guideline text 5 (Mar 2005 - Oct 2006) 3 (Jan - Feb 2007)
Cancer with pain
(Sept 2005 - Sept 2007)
Minutes, drafts, and final guideline text 5 (Sept 2005 - May 2007) 2 (Dec 2006)
Colorectal cancer
(Jan 2005 - Jan 2008)
Minutes, drafts, and final guideline text 3 (Sept 2006 - Apr 2007) 3 (Jan - Feb 2007)
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Analysis
Based on the findings from other studies,3,22 we defined a 
value judgement as a statement about the value of a patient 
outcome with regard to palliative chemotherapy. As an 
example, the aim of prolonging life with two months could 
be considered as a value judgement in recommending a 
treatment for patients with metastatic cancer. The research 
questions were guiding in the analysing process. MAXqda® 
software was used for open coding and identifyiwng 
themes in the transcripts of observations and interviews.14 
The codes were categorised by sorting the data by theme. 
Text analysis of draft and final guideline documents 
supported refining the categories. We compared categories 
of different value judgements with the guideline text15 
and examined the presence or absence of arguments 
supporting the value judgements. We excluded judgements 
on the availability of resources, cost and organisational 
issues. 
r E s U l T s 
Nine out of fourteen observed GDG meetings had palliative 
chemotherapy on the agenda, but the subject was discussed 
at only five meetings. During these meetings, most 
discussions about palliative chemotherapy dealt with 
patient quality of the individually evaluated studies related 
to the overall evidence. We seldom encountered explicit 
statements on the value of a certain patient outcome. Table 
3 illustrates how we identified a small number of value 
judgements while observing the prostate cancer GDG.
In the interviews, the 20 respondents did not spontaneously 
mention value judgements as being important to the 
guideline development process. Evidence-based medicine 
and guidelines were primarily associated with scientific 
research and empirical studies. Most of them also assumed 
that the strength of the recommendations is determined by 
the strength of the evidence. According to respondents, the 
GDG’s expert opinion would only be needed if there was 
non-inclusive evidence or inconsistent findings. 
The meeting minutes mentioned organisational issues 
but no value judgements. Drafts and final guideline 
texts included a few statements about the perceived value 
of evidence-based outcomes. However, no details were 
provided about the background of these statements. 
For example, no motivation or further specification was 
provided for the recommendation ‘Benefits and burdens 
of docetaxel in metastatic hormone-refractory prostate 
carcinoma should be considered’. Based on observations 
and interviews, it appeared that GDG members were in 
doubt about the best moment to start docetaxel and about 
whether to offer this palliative chemotherapy to frail, 
elderly men. 
Value judgements in developing guidelines for palliative 
chemotherapy
We identified four value judgements in the 
guideline development process that influenced final 
recommendations. 
Consensus on what should be considered as minimum 
patient outcomes
If there is sufficient evidence available on the effectiveness 
of palliative chemotherapy, the GDGs often agreed on a 
‘valuable minimum’ for deciding whether the treatment 
should be recommended. There seemed to be consensus 
about the minimum results on certain patient outcomes: 
Table 2. Interview topics
subjects Examples of questions
Ethical 
aspects
What do you consider to be an ethical aspect of 
guideline development? 
Do you agree with our definition of value judgements?
Process How did you determine what should be the standard 
of care? 
Could you provide examples of statements about the 
value of a patient outcome in the GDG discussions?
How did the different specialties work together in 
the GDG? 
Specific Why did you say … during that meeting …?
Although it was discussed in the GDG meetings, why 
didn’t you mention … in the guideline document?
General Do you believe recommendations for curative con-
ditions should be distinguished from non-curative 
conditions? In what way?
Table 3. Examples of observational notes and implicit value judgements
observational notes Value judgements
In the discussion on the value of docetaxel, one GDG member questioned whether 
docetaxel should become the standard treatment, because prolonging life by two months 
could be considered to be a very marginal outcome in patients who have had this disease for 
years.
Considering disease-specific patient 
outcomes is important.
Another GDG member replied that the studies were the first to show a significant increase 
in survival time. Obviously, the benefits of the treatment should be weighed against the 
burdens.
Prolonging life is important.
The treatment could be offered to younger patients who are in good condition, have an 
aggressive tumour, and want to be treated.
Tailored treatment is important.
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I believe that palliative chemotherapy can only be considered a 
standard if the response rate is at least 30%. Some people would 
say 20%, but, obviously, if the response rate is lower you cannot 
recommend this as standard therapy. (respondent Breast 4) 
Some respondents referred to the PASKWIL criteria 
developed by the Medicines Evaluation Board in the 
Netherlands (Beoordeling Oncologische Middelen in Dutch)
(table 4). For example, for the outcome ‘survival’ in 
metastatic disease, these criteria set a minimum of 
prolonging life by at least six weeks. 
A valuable minimum patient outcome specified per disease 
(rather than a consensus on what should be considered 
as valuable minimum for all diseases) was rarely used. 
However, some respondents highlighted the specific 
disease context: 
Patients with metastatic prostate cancer are often frail and 
elderly and have known for years that they have cancer. 
For them, a few extra months would not be as important 
as for patients with colorectal cancer who are younger and 
asymptomatic. (respondent Colorectal 1).  
and an explicit preference for treatment. Respondents 
in the interviews mentioned different criteria used in 
practice, such as a drop in haemoglobin or a rise in 
lactate dehydrogenase or prostate specific antigen (PSA) 
(respondents Prostate 2 and Prostate 3). However, these 
criteria were not mentioned in the guideline because of 
lack of evidence. Nevertheless, the strong conclusion in 
the prostate guideline (level 1, two randomised controlled 
trials (RCTs) with positive results) was translated into a 
weak recommendation (‘…might be offered to patients’, 
instead of: ‘… should be offered’) because the GDG wanted 
to allow professional freedom in tailoring the treatment to 
the individual patient. 
In the colorectal guideline, the GDG decided to describe 
different treatment options and leave the actual treatment 
decision to the physicians, for instance whether to use 
mono-chemotherapy or combination-chemotherapy, or 
choosing between oxaliplatin and irinotecan. One of the 
respondents explained how he tailored the therapy for 
certain patients (and groups of patients): 
…you can make a ‘tailored decision’. If the patient needs 
to be progression-free in six months, it would be better to 
give combination chemotherapy, and if the patient doesn’t 
want to go bald you shouldn’t give irinotecan. (respondent 
Colorectal 2) However, only options were provided in the 
guideline text. Considerations how to weigh these options 
were not mentioned. 
Preference for ‘doing something’
We found that physicians in the GDGs preferred to offer at 
least some kind of intervention to patients with metastatic 
cancer, even if there was sufficient evidence of no effect. 
For example, estramustine was a standard therapy for 
patients with metastatic, hormone-resistant prostate cancer 
(HRPC) before docetaxel became a standard therapy (in an 
earlier guideline that is not evaluated in this study). 
At that time estramustine was the only drug available and 
therefore at least ‘something’ could be offered. (respondent 
Prostate 1) 
Physicians also believed patients attached value to ‘doing 
something’. One guideline developer told about patients’ 
preferences with regard to the best moment in time to start 
docetaxel:
The patient wants to start as soon as possible because he finds 
it hard to do nothing. (respondent Prostate 2)
However, there was no evidence available that showed 
that an early start in patients with raised PSA but 
no other symptoms was better than a later start once 
other symptoms of metastasis had occurred. The 
recommendations of the final guideline just mentioned 
that: 1) Patients with HRPC can be offered docetaxel, and 
2) in asymptomatic HRPC patients who do not prefer 
Table 4. PASKWIL criteria for metastatic disease
Criteria fulfilled/satisfied (difference 
between standard or best sup-
portive care)
Palliative:
Response rate• 
Time to treatment failure• 
Time to progression• 
Survival (median, after 1 • 
year)
>20%
>6 weeks
>6 weeks
>6 weeks, and >20%
Side effects:
Lethal• 
Acute, serious (admission)• 
Chronic (restrictive)• 
<5%
<25%
<10%
Impact of treatment:
Clinics• 
Outpatient • 
<5 days
<3 days
Quality of life:
Performance status (PS), • 
WHO/Karnofski
Stabile PS, Time to progres-• 
sion to PS
>20% improvement
>6 weeks
Level of evidence One or more phase III study/
meta-analysis
Costs No criterion
Preference for tailored treatment
In situations without evidence of treatment effect (which 
should be distinguished from ‘evidence of no effect’) or 
in the case of equal treatment options, GDGs preferred 
to tailor the treatment to the individual patient, weighing 
up the benefits and harms. For example, one member of 
the prostate cancer GDG proposed during an observed 
GDG meeting only offering palliative chemotherapy 
(docetaxel) to young patients who had an aggressive tumour 
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docetaxel, a symptomatic treatment is recommended. No 
background information was given to support decision 
making. 
We found one clear exception to the tendency to value 
‘something’ over ‘nothing’. The oesophageal carcinoma 
guideline (2005) clearly stated in the conclusion that: 
(…), chemotherapy cannot be considered to be a standard 
of care. It is preferable to use chemotherapy exclusively in 
studies.
Although chemotherapy was not considered to be a 
standard of care, in fact again ‘something’ was offered in 
the form of chemotherapy in the context of research. 
Prolonging life
We found that GDGs often considered prolonging life to be 
the most important patient outcome: 
What you notice is that a working group is focused on ‘curing’ 
the disease, with quality of life getting less attention. Apart 
from those treatments, the side effects of treatments could be a 
focus too, to see how you could treat them and what evidence 
there is for this. (respondent Oesophagus 5) 
Several respondents stated that this tendency could be 
explained by the difficulty in measuring quality of life and 
also the average patient’s preference to live as long as possible. 
For example, prolonging life was the only decisive patient 
outcome when docetaxel became the standard of care. 
Palliative chemotherapy was considered for potential 
chemotherapy-sensitive tumours in the ‘cancer with pain’ 
GDG. Although two respondents emphasised that palliative 
chemotherapy would never be administered only for pain 
reduction, prolonging life should also be attempted if possible 
(respondents Pain 1 and Pain 2). The fact that prolonging life 
is mentioned even in an area where pain reduction is the 
main goal underlines how highly this is valued. 
Value judgements in the final guideline report
Although we encountered different value judgements 
during guideline development, often they were not reflected 
in the final guideline text. In the interviews, respondents 
gave several reasons for the lack of explicitness: 
The treatment of a metastatic disease depends to a great 1. 
extent on the preferences of the individual patient. This 
conflicts with a guideline that should be applicable for 
all patients. Therefore, respondents said that GDGs 
limited their job to summarising the statistically 
significant effects.
The section in the guidelines about palliative 2. 
chemotherapy was often drafted by medical oncologists. 
As the interest of GDG members is often limited to their 
own field of expertise, the value of chemotherapy was 
not always discussed in detail in the GDG meetings: 
Although surgeons might think that chemotherapy is 
terrible for the patient, they will leave the decision up to 
medical oncologists because it is our profession (respondent 
Breast 4) 
The GDGs aimed to limit the length of the guideline. 3. 
Detailed considerations were not included for reasons 
of readability. 
d i s C U s s i o N 
In this study, we determined several value judgements 
used in developing guidelines for palliative chemotherapy. 
However, often these value judgements were not explicitly 
mentioned in the final guideline report. As a consequence, 
patients with incurable metastatic disease may not be aware 
of relevant value judgements. We believe that for patients in 
the process of making decisions about their treatment, at least 
two of the four encountered value judgements are important: 
the preference for ‘doing something’ and for prolonging life. 
A patient should know that chemotherapy could be offered 
because physicians find it hard to ‘do nothing’ and believe 
that patients value ‘doing something’ and prolonging life 
above ‘watchful waiting’. Such value judgements are not 
mentioned in the guideline but play an important role in 
determining the standard of care as expressed in the final 
recommendations in oncology guidelines. 
We believe that the lack of explicitness about value 
judgements may be due to broad consensus between 
medical oncologists about routine care and the widespread 
association of evidence-based clinical practice guidelines 
with objectivity, thus excluding value judgements. 
However, value judgements about patient outcomes 
are inevitable in guideline development. These value 
judgements distinguish a guideline from a review of 
literature. In the guideline text the conclusions are based 
on scientific literature, which are graded using a scale 
from level 1 (one systematic review or two or more 
RCTs) to level 4 (expert opinion). Beyond the evidence, 
‘other considerations’, including the value judgements 
that we found, can play an important role in translating 
the conclusion to recommendations. The wording of 
recommendations (for instance using terms as ‘must’, 
‘should’, ‘could’) reflects both the level of the conclusion 
and the weight of the other considerations. One might 
argue that if the considerations and value judgements 
were more explicitly described, the length of the guideline 
could hamper the implementation of the guideline. This 
would not be a problem, however, if summary guides and 
tools for application (such as patient leaflets) are provided 
to facilitate the guideline’s use in practice. 
As far as we know, this is the first study on value 
judgements in oncology guidelines. We studied the process 
of the development of six oncology guidelines in the 
Netherlands. Our analysis of a sample of evidence-based 
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oncology guidelines developed in other countries confirmed 
our findings: recommendations for palliative chemotherapy 
are rarely explained and value judgements have not been 
made explicit in these guidelines.16-20 Berg et al. studied 
value judgements in guidelines on depression and angina 
pectoris and came to the same conclusion.8 
Strength of our study is the use of three different methods 
of data collection. We know from the literature that the 
process of guideline development is influenced by group 
dynamics and the composition of the GDG.21-23 By using 
semi-structured interviews as a data source (in addition to 
observations and text analysis), we used ‘triangulation’ to 
increase the consistency of findings.24
A limitation of our study is that we observed plenary 
GDG meetings and might have missed small group 
discussions and discussions via email. Even if we did 
miss certain value judgements, these were not reflected 
in the final guideline reports. Furthermore, we excluded 
costs and other organisational issues. We report on 
different opinions for including/excluding cost issues 
in guidelines in another paper from this project.25 We 
also excluded value judgements that had already been 
made in evaluated studies during guideline development. 
In a separate paper for this project, we report on the 
importance of prolonging life compared with quality of 
life in interpreting randomised controlled trial results on 
palliative chemotherapy.26 
The quality of guidelines for the treatment of metastatic 
cancer could be improved by making value judgements 
explicit and by providing tools for weighing up the pros and 
cons of different treatment options.27 Then, the guideline 
user (the physician) will be able to discuss the relevant 
value judgements with his or her patient.28 A checklist 
of potential values could support this process (appendix 
1). Both physicians and patient representatives involved 
in the development of guidelines should be trained in 
making value judgements more explicit. Guidelines should 
ultimately focus on improving individual patient care, 
and being explicit about value judgements is essential to 
this.29
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